Princeton Capital Management’s Biolase, Inc. BIOL Stock Holding History

Princeton Capital Management’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Hold	0	–	–	–	232
2019 Q3	–	Hold	0	–	–	–	256
2019 Q2	–	Hold	0	–	–	–	255
2019 Q1	–	Hold	0	–	–	–	258
2018 Q4	–	Hold	0	–	–	–	273
2018 Q3	–	Sell	-12	Closed	-$48K	–	292
2018 Q2	$36K	Buy	12 +10	+500%	+$37.7K	0.02%	190
2018 Q1	$12K	Hold	2	–	–	0.01%	238
2017 Q4	$13K	Buy	+2	New	+$14.1K	0.01%	99

Other funds holding BIOL

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $355M AUM 45.63% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Princeton Capital Management's BIOL Position: Q4 2019 in Review

Princeton Capital Management held its Biolase, Inc. (BIOL) position steady in Q4 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #232.

Princeton Capital Management first reported a position in BIOL in Q4 2017 and has held it in 3 quarters since. The position peaked at $36K in Q2 2018. 19 funds tracked by Wall St. Rank hold BIOL as of Q4 2019.

Princeton Capital Management held 0 shares of Biolase, Inc. worth $0 as of Q4 2019.
Princeton Capital Management left its Biolase, Inc. share count unchanged in Q4 2019.
Biolase, Inc. made up ﹤0.01% of Princeton Capital Management's portfolio in Q4 2019, its #232 holding.
Princeton Capital Management first reported a position in Biolase, Inc. in Q4 2017 and has held it in 3 quarters since.
Princeton Capital Management's Biolase, Inc. position peaked at $36K in Q2 2018.
19 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2019.

Based on Princeton Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.